Novartis Says Genentech Won't Return $210M IP Overpayment
Genentech improperly failed to alert Novartis Pharma AG that it was overpaying tens of millions of dollars on a patent licensing deal, then refused to return more than $209.5 million in...To view the full article, register now.
Already a subscriber? Click here to view full article